Amgen - Prolia: ouch!

Amgen announced Monday that the FDA issued a complete response letter related to its filing for Prolia (denosumab) in the treatment and prevention of postmenopausal osteoporosis. The agency requested a new clinical programme to support approval of Prolia for the prevention indication. Full story